Published in Nat Med on June 04, 2006
Soluble Factors and Renal Outcome in Preeclampsia | NCT04940260
Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One (2008) 3.46
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med (2008) 3.36
Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol (2009) 3.05
Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet (2009) 2.83
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia. Clin Sci (Lond) (2009) 2.31
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Renal albumin filtration: alternative models to the standard physical barriers. Nat Rev Nephrol (2013) 2.24
Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol (2010) 2.04
The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol (2010) 1.99
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells (2009) 1.84
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia. J Matern Fetal Neonatal Med (2009) 1.84
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
Critical growth factors and signalling pathways controlling human trophoblast invasion. Int J Dev Biol (2010) 1.70
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
The placenta: transcriptional, epigenetic, and physiological integration during development. J Clin Invest (2010) 1.61
The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age. J Matern Fetal Neonatal Med (2008) 1.60
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A (2010) 1.56
Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med (2015) 1.54
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Analysis of microarray experiments of gene expression profiling. Am J Obstet Gynecol (2006) 1.53
Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol (2011) 1.50
Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab (2007) 1.49
Roles for VEGF in the adult. Microvasc Res (2007) 1.48
Soluble endoglin specifically binds bone morphogenetic proteins 9 and 10 via its orphan domain, inhibits blood vessel formation, and suppresses tumor growth. J Biol Chem (2011) 1.48
Preeclampsia: multiple approaches for a multifactorial disease. Dis Model Mech (2012) 1.48
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension (2008) 1.45
Potential markers of preeclampsia--a review. Reprod Biol Endocrinol (2009) 1.44
TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One (2009) 1.38
TGFβ signaling and cardiovascular diseases. Int J Biol Sci (2012) 1.35
Novel biochemical pathways of endoglin in vascular cell physiology. J Cell Biochem (2007) 1.34
Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy. Nature (2012) 1.30
A critical role of interleukin-10 in modulating hypoxia-induced preeclampsia-like disease in mice. Hypertension (2011) 1.28
BMP signaling in vascular development and disease. Cytokine Growth Factor Rev (2010) 1.26
Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J Cell Mol Med (2009) 1.24
A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. Am J Physiol Heart Circ Physiol (2012) 1.24
The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol (2010) 1.23
A brief overview of preeclampsia. J Clin Med Res (2013) 1.23
Novel biomarkers for predicting preeclampsia. Trends Cardiovasc Med (2008) 1.20
Preeclampsia 2012. J Pregnancy (2012) 1.20
Genetics of preeclampsia: paradigm shifts. Hum Genet (2006) 1.18
The biology of preeclampsia. Kidney Int (2009) 1.16
Endoglin expression in blood and endothelium is differentially regulated by modular assembly of the Ets/Gata hemangioblast code. Blood (2008) 1.16
Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol (2009) 1.14
Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet Gynecol (2010) 1.14
Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia. J Matern Fetal Neonatal Med (2011) 1.13
Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ Res (2013) 1.13
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation (2012) 1.12
Comparative gene expression profiling of placentas from patients with severe pre-eclampsia and unexplained fetal growth restriction. Reprod Biol Endocrinol (2011) 1.11
Compartmentalizing VEGF-induced ERK2/1 signaling in placental artery endothelial cell caveolae: a paradoxical role of caveolin-1 in placental angiogenesis in vitro. Mol Endocrinol (2009) 1.11
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension (2008) 1.10
The role of endothelial cell injury in thrombotic microangiopathy. Am J Kidney Dis (2010) 1.10
Pre-eclampsia and cardiovascular disease. Cardiovasc Res (2014) 1.10
Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: expression of Flt-1 and endoglin. PLoS One (2013) 1.10
Targeting the tumor microenvironment: focus on angiogenesis. J Oncol (2011) 1.09
Is inflammation the cause of pre-eclampsia? Biochem Soc Trans (2011) 1.09
Nodal signals through activin receptor-like kinase 7 to inhibit trophoblast migration and invasion: implication in the pathogenesis of preeclampsia. Am J Pathol (2011) 1.09
Transcriptional profiling of human placentas from pregnancies complicated by preeclampsia reveals disregulation of sialic acid acetylesterase and immune signalling pathways. Placenta (2010) 1.09
A subset of patients destined to develop spontaneous preterm labor has an abnormal angiogenic/anti-angiogenic profile in maternal plasma: evidence in support of pathophysiologic heterogeneity of preterm labor derived from a longitudinal study. J Matern Fetal Neonatal Med (2009) 1.09
Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta (2010) 1.08
First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol (2008) 1.08
Late-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion. J Matern Fetal Neonatal Med (2011) 1.07
HELLP babies link a novel lincRNA to the trophoblast cell cycle. J Clin Invest (2012) 1.07
Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol (2007) 1.07
Transforming Growth Factor-β and Endoglin Signaling Orchestrate Wound Healing. Front Physiol (2011) 1.07
miR-210 targets iron-sulfur cluster scaffold homologue in human trophoblast cell lines: siderosis of interstitial trophoblasts as a novel pathology of preterm preeclampsia and small-for-gestational-age pregnancies. Am J Pathol (2011) 1.06
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05
Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. PLoS One (2012) 1.05
Epistasis between COMT and MTHFR in maternal-fetal dyads increases risk for preeclampsia. PLoS One (2011) 1.04
Prediction and prevention of hypertensive disorders of pregnancy. Hypertens Res (2016) 1.04
Reversal of gene dysregulation in cultured cytotrophoblasts reveals possible causes of preeclampsia. J Clin Invest (2013) 1.03
The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med (2010) 1.03
Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia. Circulation (2010) 1.03
Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney Int (2014) 1.03
The zebrafish as a tool to identify novel therapies for human cardiovascular disease. Dis Model Mech (2014) 1.03
Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. Cardiovasc Res (2010) 1.02
Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem (2010) 1.02
Placental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsia. J Perinat Med (2011) 1.01
Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-beta 3. Am J Pathol (2007) 1.00
A lesson for cancer research: placental microarray gene analysis in preeclampsia. Oncotarget (2012) 0.99
Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med (2012) 0.99
Adenoviral delivery of VEGF121 early in pregnancy prevents spontaneous development of preeclampsia in BPH/5 mice. Hypertension (2010) 0.99
Isolation of periportal, midlobular, and centrilobular rat liver sinusoidal endothelial cells enables study of zonated drug toxicity. Am J Physiol Gastrointest Liver Physiol (2010) 0.99
CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia? J Matern Fetal Neonatal Med (2007) 0.99
In vitro and in vivo evidence for lack of endovascular remodeling by third trimester trophoblasts. Placenta (2008) 0.99
Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med (2010) 0.99
Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Ther Adv Cardiovasc Dis (2008) 0.99
Placental expression of ceruloplasmin in pregnancies complicated by severe preeclampsia. Lab Invest (2008) 0.99
Angiogenesis and hypoxia in the kidney. Nat Rev Nephrol (2013) 0.99
Soluble endoglin modulates aberrant cerebral vascular remodeling. Ann Neurol (2009) 0.98
Murine pregnancy-specific glycoprotein 23 induces the proangiogenic factors transforming-growth factor beta 1 and vascular endothelial growth factor a in cell types involved in vascular remodeling in pregnancy. Biol Reprod (2008) 0.98
Differentially expressed genes in the pre-eclamptic placenta: a systematic review and meta-analysis. PLoS One (2013) 0.97
Adiponectin in severe preeclampsia. J Perinat Med (2007) 0.97
Epidemiology and causes of preterm birth. Lancet (2008) 18.96
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Comment on " 'Stemness': transcriptional profiling of embryonic and adult stem cells" and "a stem cell molecular signature". Science (2003) 8.79
BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med (2003) 7.91
Engineering vascularized skeletal muscle tissue. Nat Biotechnol (2005) 7.73
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
A systems biology approach for pathway level analysis. Genome Res (2007) 6.95
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation (2013) 5.02
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Genomic counter-stress changes induced by the relaxation response. PLoS One (2008) 3.86
Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest (2005) 3.77
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. J Clin Invest (2002) 3.70
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol (2008) 3.65
2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 3.63
2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg (2014) 3.59
Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PLoS One (2008) 3.46
A mechanosensitive transcriptional mechanism that controls angiogenesis. Nature (2009) 3.44
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science (2012) 3.33
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
An evidence-based review of the practice of cardiopulmonary bypass in adults: a focus on neurologic injury, glycemic control, hemodilution, and the inflammatory response. J Thorac Cardiovasc Surg (2006) 3.09
Derivation and validation of a preoperative prediction rule for delirium after cardiac surgery. Circulation (2008) 3.06
Microbial prevalence, diversity and abundance in amniotic fluid during preterm labor: a molecular and culture-based investigation. PLoS One (2008) 3.01
Drug discovery. Repurposing with a difference. Science (2009) 2.97
Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol (2004) 2.91
Primary, secondary, and tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet (2008) 2.90
Distinct subsets of microRNAs are expressed differentially in the human placentas of patients with preeclampsia. Am J Obstet Gynecol (2007) 2.78
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol (2006) 2.74
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res (2005) 2.67
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
A high-fat, ketogenic diet induces a unique metabolic state in mice. Am J Physiol Endocrinol Metab (2007) 2.64
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci U S A (2009) 2.59
Wheat amylase trypsin inhibitors drive intestinal inflammation via activation of toll-like receptor 4. J Exp Med (2012) 2.58
Machine learning and its applications to biology. PLoS Comput Biol (2007) 2.57
Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development (2002) 2.57
Confocal light absorption and scattering spectroscopic microscopy monitors organelles in live cells with no exogenous labels. Proc Natl Acad Sci U S A (2007) 2.56
Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol (2004) 2.56
Failure of physiologic transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol (2003) 2.55
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Skeletonized internal thoracic artery harvest reduces pain and dysesthesia and improves sternal perfusion after coronary artery bypass surgery: a randomized, double-blind, within-patient comparison. Circulation (2006) 2.54
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther (2009) 2.43
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev (2002) 2.42
The fetal inflammatory response syndrome. Clin Obstet Gynecol (2007) 2.36
Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int (2005) 2.32
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
The association of perioperative red blood cell transfusions and decreased long-term survival after cardiac surgery. Anesth Analg (2009) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Decreased macrophage number and activation lead to reduced lymphatic vessel formation and contribute to impaired diabetic wound healing. Am J Pathol (2007) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Antimyeloma activity of heat shock protein-90 inhibition. Blood (2005) 2.24
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension (2005) 2.22